<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">AAPS PharmSci</journal-id><journal-id journal-id-type="pmc-domain-id">989</journal-id><journal-id journal-id-type="pmc-domain">pharmsci</journal-id><journal-title-group><journal-title xml:lang="en">AAPS PharmSci</journal-title></journal-title-group><issn pub-type="epub">1522-1059</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2761142</article-id><article-id pub-id-type="pmcid-ver">PMC2761142.1</article-id><article-id pub-id-type="pmcaid">2761142</article-id><article-id pub-id-type="pmcaiid">2761142</article-id><article-id pub-id-type="pmid">11741248</article-id><article-id pub-id-type="doi">10.1208/ps020332</article-id><article-id pub-id-type="publisher-id">23123</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Nonlinearity detection: Advantages of nonlinear mixed-effects modeling</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jonsson</surname><given-names initials="EN">E. Niclas</given-names></name><address><phone>46-18-471-4685</phone><fax>46-18-471-4003</fax><email>niclas.jonsson@biof.uu.se</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karlsson</surname><given-names initials="MO">Mats O.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wade</surname><given-names initials="JR">Janet R.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Box 580, S-751 23 Uppsala, Sweden </aff><aff id="Aff2"><label>2</label>Medical Products Agency, Box 26, S-751 03 Uppsala, Sweden </aff></contrib-group><pub-date pub-type="collection"><month>9</month><year>2000</year></pub-date><pub-date pub-type="epub"><day>25</day><month>9</month><year>2000</year></pub-date><volume>2</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">182198</issue-id><fpage>114</fpage><lpage>123</lpage><history><date date-type="received"><day>4</day><month>2</month><year>2000</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>09</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>14</day><month>10</month><year>2009</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2013-04-03 20:05:30.310"><day>03</day><month>04</month><year>2013</year></date></event></pub-history><permissions><copyright-statement>&#169; American Association of Pharmaceutical Scientists 2000</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12248_2008_Article_23123.pdf"/><abstract xml:lang="en"><p>The purpose of this study was to address the question of whether the use of nonlinear mixed-effect models has an impact on the detection and characterization of nonlinear processes (pharmacokinetic and pharmacodynamic) in rich data obtained from a few subjects. Simulations were used to assess the difference between applying population analysis, ie, nonlinear mixed-effects models as implemented in NONMEM, and the standard 2-stage (STS) method as the data analysis method for detection and characterization of nonlinearities. Three situations were considered, 2 pharmacokinetic and 1 pharmacodynamic. Both the first-order (FO) and FO conditional estimation (FOCE) algorithms were used for the population analyses. Within each situation, rich data were simulated for 8 subjects at multiple dose levels. The true nonlinear model and a simpler linear model were fit to each data set using each of the STS, FO, and FOCE methods. Criteria were prespecified to determine when each data analysis method detected the true nonlinear model. For all 3 simulated situations, the application of population analysis with the FOCE algorithm enabled the detection and characterization of the true nonlinear models in at least a 4-fold lower dose level than the STS approach. For both of the pharmacokinetic settings, population analysis with the FO algorithm performed much more poorly than the STS approach. The superior detection and characterization of nonlinearities provided by population analysis with the FOCE algorithm should allow drug developers to better predict and define how a drug should be used in clinical practice in such situations.</p></abstract><kwd-group><title>Key words</title><kwd>Population Analysis</kwd><kwd>Nonlinear Mixed-Effects Modeling</kwd><kwd>Nonlinear Pharmacokinetics and Pharmacodynamics</kwd><kwd>Study Design</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; American Association of Pharmaceutical Scientists 2000</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>